Date Time
Share
Bone treatment startup raises $5.5 M in Series A financing, names pharmaceutical leader William Boyle as CEO
The image above shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site. The “targeted” bone received Novosteo’s injectable-targeted drug, whereas the control bone did not receive drug, representing current therapies. Comparing the two bones, the additional bone growth caused by Novosteo’s drug could help people with fractures return to normal activity quickly in the future. (Image provided by Novosteo Inc.)